Debt issuance costs expensed under the fair value option
-
-
0
147
Non-cash lease expense
271
285
400
312
Other
-96
-27
-32
-28
Prepaid expenses and other assets
645
794
2,135
-971
Accounts payable
4,557
1,289
-2,126
-1,948
Accrued expenses and other liabilities
859
-5,149
2,674
5,008
Deferred revenue
-
-
-5,485
0
Net cash used in operating activities
-40,425
-40,878
-26,722
-24,166
Purchase of research and development license
0
3,000
-
-
Purchase of property, plant and equipment
-1
24
250
108
Other
-
-
-3
-60
Net cash used in investing activities
1
-3,024
-247
-48
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs
216,139
-
-70
-454
Proceeds from issuance of common stock pursuant to at-the-market offering, net of sales commissions and other offering costs
-
-
48,435
-
Prepayment of 2023 trinity term loan
-
-
0
40,612
Proceeds from 2025 trinity term loan, net
-
-
0
49,853
Payment of shelf registration costs
-
-
-
-14
Proceeds from issuance of common stock upon exercise of warrants
-
-
225
-
Proceeds from common stock issuances under espp
0
176
0
84
Proceeds from stock option exercises
441
516
1,023
197
Other
75
19
-90
-285
Net cash provided by financing activities
216,655
711
49,556
8,797
Net increase in cash, cash equivalents and restricted cash
176,231
-43,191
22,587
-15,417
Cash, cash equivalents and restricted cash at the beginning of the period
279,340
322,531
299,944
141,636
Cash, cash equivalents and restricted cash at the end of the period
455,571
279,340
322,531
299,944
Cash and cash equivalents
455,407
-
-
-
Restricted cash
164
-
-
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.